Wire · opportunities
FDA Clears C2N's PrecivityAD2 Alzheimer's Blood Test for Ages 40+
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 August 2026 · Fusion42 review
The FDA cleared C2N Diagnostics’ PrecivityAD2 Alzheimer’s blood test for use in adults aged 40 and older showing cognitive impairment signs, marking it as the first such FDA-cleared test for this younger symptomatic group. The test offers high predictive accuracy using mass spectrometry to identify amyloid pathology and aims to enable earlier diagnosis and clinical trial participation.
This Wire brief sits within Fusion42's coverage of Diagnostics, and 8 sources have reported it between 20 Aug 2026 and 21 Aug 2026.
◆ ◆ The Wire takeaway
You can now target earlier-stage Alzheimer’s patients aged 40-plus with validated diagnostic tools that clear the FDA. This opens paths into clinical care and trials by speeding diagnosis far ahead of symptom onset.
◆ Coverage
8 sources · first reported 20 Aug 2026 · latest 21 Aug 2026
◆ Related on Wire
◆ Topics